Bolt Biotherapeutics, Inc. Finance Lease, Right-of-Use Asset, after Accumulated Amortization
Bolt Biotherapeutics, Inc. (BOLT) had Finance Lease, Right-of-Use Asset, after Accumulated Amortization of $21.00 thousand as of 2021-09-30, per its 10-Q filed 2021-11-09.
Discontinued › Balance Sheet › Assets, Noncurrent
us-gaap:FinanceLeaseRightOfUseAsset · last filed 2021-11-09
- 2021-09-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $21.00K.
- 2021-06-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $25.00K.
- 2021-03-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $30.00K.
- 2020-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $34.00K.
| Period end | Finance Lease, Right-of-Use Asset, after Accumulated Amortization |
|---|---|
| 2021-09-30 | $21.00K 10-Q · filed 2021-11-09 |
| 2021-06-30 | $25.00K 10-Q · filed 2021-08-12 |
| 2021-03-31 | $30.00K 10-Q · filed 2021-05-13 |
| 2020-12-31 | $34.00K 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |